Table 4.
Clinical outcomes in patients with primary membranous nephropathy according to presence of anti-PLA2R ab
| Variable | Anti-PLA2R(+) | Anti-PLA2R(−) | P value |
|---|---|---|---|
| Number of patients | 25 | 23 | |
| CKD stage 3 or more | 10 (40.0) | 2 (8.7) | 0.012 |
| CKD stage 5 | 3 (12.0) | 1 (4.3) | 0.338 |
| Remission | 15 (60.0) | 21 (91.3) | 0.012 |
| Partial remission | 9 (36.0) | 7 (30.4) | 0.683 |
| Complete remission | 6 (24.0) | 14 (60.9) | 0.010 |
| Spontaneous remission | 3 (12.0) | 17 (73.9) | < 0.001 |
Data are presented as number only or number (%).
CKD stage 3, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2; CKD stage 5, defined as eGFR < 15 mL/min/1.73 m2 and the need for dialysis; partial remission, defined as proteinuria < 3.5 g/g with a decreased of 50% from baseline; complete remission, defined as proteinuria < 0.3 g/g; spontaneous remission, partial or complete remission without immunosuppressant.
Anti-PLA2R ab, anti-phospholipase A2 receptor antibody; CKD, chronic kidney disease.